Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 09, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 370,000 ordinary shares of 25 pence each.
- Purchase Date: September 06, 2005.
- Purchase Price: 1,358.4839 pence per share.
- Treasury Shares Held: 110,243,000 shares (post-purchase).
- Shares in Issue: 5,834,425,665 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 25, 2005. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 370,000 shares purchased at 1,358.4839 pence per share.
- Confirm the remaining authorization limit for share buybacks following this transaction.
- Check subsequent filings for the final disposition of the 110,243,000 Treasury shares.